Recent Advances in Epitope Design for Immunotherapy of Cancer

被引：18
作者：
Chiarella, Pieranna [1 ,2 ]
Massi, Emanuela [1 ,2 ]
De Robertis, Mariangela [1 ,2 ]
Fazio, Vito M. [1 ,3 ]
Signori, Emanuela [1 ,2 ]
机构：
[1] Univ Rome, CIR, Lab Mol Med & Biotechnol, I-00128 Rome, Italy
[2] CNR, Inst Neurobiol & Mol Med, Lab Mol Pathol & Expt Oncol, I-00133 Rome, Italy
[3] IRCCSH Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, FG, Italy
来源：
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY | 2009年 / 4卷 / 03期
关键词：
Cancer; clinical trials; epitope enhancement; immunotherapy; 'in silico' prediction; tumour antigens; vaccine; web-based tools; CD4(+) T-CELLS; RESTRICTED EPITOPE; VACCINE DESIGN; IN-VITRO; IDENTIFICATION; PEPTIDE; ANTIGEN; PROTEIN; RESPONSES; IMMUNIZATION;
D O I：
10.2174/157489209789206922
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Eradication of cancer cells is imperative for a successful treatment of tumours. In addition to the existent chemotherapy or radiation therapy, other novel immunotherapeutic strategies to fight tumours are currently under investigation. One of these is cancer vaccination, an approach aimed at inducing effective immune responses in the host against defined tumour antigens. Among several classes of cancer vaccines, the subunit vaccines based on the single and multi epitope-approach are worthy of note as they offer an exquisite specificity in targeting only tumour cells. In this review we will focus on the significant advances made in the development and use of epitope-based cancer vaccines, reporting a selection of important and recent patents on tumour antigen discovery and epitope design for immunotherapy of cancer.
引用
收藏
页码：227 / 240
页数：14
相关论文
共 132 条
[1]   Rational antigen modification as a strategy to upregulate or downregulate antigen recognition [J].
Abrams, SI ;
Schlom, J .
CURRENT OPINION IN IMMUNOLOGY, 2000, 12 (01) :85-91
[2]   Ligand-targeted therapeutics in anticancer therapy [J].
Allen, TM .
NATURE REVIEWS CANCER, 2002, 2 (10) :750-763
[3]  
[Anonymous], 2007, Global Cancer Facts Figures
[4]  
BABE LM, 2007, Patent No. 20070037151
[5]   Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes:: Clinical and immunologic findings [J].
Belli, F ;
Testori, A ;
Rivoltini, L ;
Maio, M ;
Andreola, G ;
Sertoli, MR ;
Gallino, G ;
Piris, A ;
Cattelan, A ;
Lazzari, I ;
Carrabba, M ;
Scita, G ;
Santantonio, C ;
Pilla, L ;
Tragni, G ;
Lombardo, C ;
Arienti, F ;
Marchianò, A ;
Queirolo, P ;
Bertolini, F ;
Cova, A ;
Lamaj, E ;
Ascani, L ;
Camerini, R ;
Corsi, M ;
Cascinelli, N ;
Lewis, JJ ;
Srivastava, P ;
Parmiani, G .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4169-4180
[6]   Immunization of HLA class I transgenic mice indentifies autoantigenic epitopes eliciting dominant responses in type 1 diabetes patients [J].
Blancou, Philippe ;
Mallone, Roberto ;
Martinuzzi, Emanuela ;
Severe, Sabine ;
Pogu, Sylvie ;
Novelli, Giulia ;
Bruno, Graziella ;
Charbonnel, Bernard ;
Dolz, Manuel ;
Chaillous, Lucy ;
van Endert, Peter ;
Bach, Jean-Marie .
JOURNAL OF IMMUNOLOGY, 2007, 178 (11) :7458-7466
[7]  
Bonnotte B, 1998, J IMMUNOL, V161, P1433
[8]   Peptide-based vaccines for cancer immunotherapy [J].
Brinkman, JA ;
Fausch, SC ;
Weber, JS ;
Kast, WM .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (02) :181-198
[9]   Th17 and cancer: friends or foes? [J].
Bronte, Vincenzo .
BLOOD, 2008, 112 (02) :214-214
[10]   Anticancer Immunotherapy in Combination with Proapoptotic Therapy [J].
Bruserud, Oystein ;
Ersvaer, Elisabeth ;
Olsnes, Astrid ;
Gjertsen, Bjorn Tore .
CURRENT CANCER DRUG TARGETS, 2008, 8 (08) :666-675
12345678910